Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AavantiBio
Cambridge, Massachusetts, United Statesaavantibio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
AavantiBio developed a pipeline of preclinical gene therapies, most notably an AAV-based candidate delivering full-length frataxin to treat both neurological and cardiac symptoms of Friedreich’s ataxia. The company also pursued programs in BAG3-mediated dilated cardiomyopathy. No clinical results have been reported as all programs remained preclinical prior to acquisition.
- Therapeutic areas
- NeurologyCardiovascular
- Modalities
- Gene therapyAAV-based gene therapy (Adeno-associated virus vector)
- Industry
- Biotech
02
Partnerships
Sarepta Therapeutics (investor/partner)University of Florida Powell Gene Therapy CenterCatalent Cell & Gene Therapy
Beyond the preview
Go deeper on AavantiBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AavantiBio.